Nov 07, 2018
RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018
Nov 06, 2018
RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018
Oct 03, 2018
RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering
Sep 26, 2018
RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference
Aug 28, 2018
RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 15, 2018
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors
Aug 14, 2018
RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
Aug 02, 2018
RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan
Aug 01, 2018
RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
Jun 28, 2018
BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury
May 18, 2018
RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone(TM) for the Treatment of Common Warts
May 10, 2018
RXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
May 01, 2018
RXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference
Apr 24, 2018
RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018
Apr 16, 2018
RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma
Apr 11, 2018
RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering
Apr 09, 2018
RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market
Apr 04, 2018
RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference
Mar 26, 2018
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights
Mar 21, 2018
RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018